Compositions and methods for modulating apolipoprotein (a) expression
Provided herein are oligomeric compounds with conjugate groups targeting apoplipoprotein (a) [apo(a)]. In certain embodiments, the apo(a) targeting oligomeric compounds are conjugated to N-Acetylgalactosamine. Also disclosed herein are conjugated oligomeric compounds targeting apo(a) for use in decreasing apo(a) to treat, prevent, or ameliorate diseases, disorders or conditions related to apo(a) and/or Lp(a). Certain diseases, disorders or conditions related to apo(a) and/or Lp(a) include inflammatory, cardiovascular and/or metabolic diseases, disorders or conditions. The conjugated oligomeric compounds disclosed herein can be used to treat such diseases, disorders or conditions in an individual in need thereof.
1. A method for treating a disease related to elevated Lp (a) comprising administering to a human in need a compound, wherein the compound has the formula:
or a pharmaceutically acceptable salt thereof.
2. The method of claim 1 , wherein the pharmaceutically acceptable salt is the sodium salt.
3. The method of claim 1 , wherein the disease is a cardiovascular, metabolic and/or inflammatory disease, disorder or condition.
4. The method of claim 1 , wherein the disease is a cardiovascular disease.
5. The method of claim 1 , wherein the disease is hyperlipidemia.
6. The method of claim 3 , wherein the disease is aneurysm, angina, arrhythmia, atherosclerosis, cerebrovascular disease, coronary artery disease, coronary heart disease myocardial infarction, peripheral vascular disease, peripheral artery disease, peripheral artery occlusive disease, retinal vascular occlusion, or stroke.
7. The method of claim 2 , wherein the disease is a cardiovascular disease.
8. A method for preventing a disease related to elevated Lp (a) comprising administering to a human in need a compound or pharmaceutically acceptable salt thereof, wherein the compound has the formula:
or a pharmaceutically acceptable salt thereof.
9. The method of claim 8 , wherein the pharmaceutically acceptable salt is the sodium salt.
10. The method of claim 8 , wherein the disease is a cardiovascular, metabolic and/or inflammatory disease, disorder or condition.
11. The method of claim 8 , wherein the disease is a cardiovascular disease.
12. The method of claim 11 , wherein the disease is hyperlipidemia.
13. The method of claim 11 , wherein the disease is aneurysm, angina, arrhythmia, atherosclerosis, cerebrovascular disease, coronary artery disease, coronary heart disease myocardial infarction, peripheral vascular disease, peripheral artery disease, peripheral artery occlusive disease, retinal vascular occlusion, or stroke.
14. The method of claim 9 , wherein the disease is a cardiovascular disease.
15. A pharmaceutically acceptable salt of a compound having the formula:
16. The pharmaceutically acceptable salt of claim 15 , wherein the pharmaceutically acceptable salt is the sodium salt.